Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL

Ascentage Pharma announced that lisaftoclax, a novel Bcl-2 inhibitor and one of the company’s core assets, has been cleared by the US Food and Drug Administration to enter a global registrational Phase III study for treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were BTKi previously treated.